Skip to content

An investigation on the visceral fat reduction effect and the safety of coffee.

An investigation on the visceral fat reduction effect and the safety of coffee. - An investigation on the visceral fat reduction effect and the safety of coffee.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000033084
Enrollment
60
Registered
2018-06-21
Start date
2018-06-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N/A(People with a BMI of at least 25 kg/m2 and less than 30kg/m2.)

Interventions

Placebo (30 patients) Coffee. Consumption period of 12 weeks. 1 drink per day. Intervention (30 patients) Coffee. Consumption period of 12 weeks. 1 drink per day.

Sponsors

Tsuguyoshi Asano
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults (men and women) who are at least 20 and under 65 years of age when Informed Consent is taken 2. People with a BMI of at least 25 kg/m2 and less than 30 kg/m2 3. People who voluntary give written informed consent to participate in the study before study begins

Exclusion criteria

Exclusion criteria: 1. People who have very irregular dietary habits 2. People on continuous treatment with medication 3. People with medicine or food allergies 4. People using medicine, foods for specified health uses, foods with functional claims, supplements, or diet products that may have an effect on the study 5. People with hypertension , diabetes mellitus, dyslipidemia ,or other lifestyle-related diseases 6. People with gastrointestinal dysfunction, significant liver dysfunction, significant kidney dysfunction, or significant cardiovascular disease 7. People with a history of a gastrectomy/extensive digestive tract excision 8. People with dependence on drugs or alcohol 9. People who are pregnant, nursing, or plan to become pregnant 10. Other people determined to be unsuitable for participation in the study by the principal investigator

Design outcomes

Primary

MeasureTime frame
Visceral Fat Measured at initial, 4 week, 8 week, and 12 week visits

Secondary

MeasureTime frame
Weight Measured at initial, 4 week, 8 week, and 12 week visits BMI Measured at initial, 4 week, 8 week, and 12 week visits Waist Circumference Measured at initial, 4 week, 8 week, and 12 week visits

Countries

Japan

Contacts

Public ContactKazuo Haruna

Increase Co., Ltd. Clinical Development Department

key001@inc-cro.co.jp03-6231-1394

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026